Overcoming Irreproducibility in Life Science Research

Sponsored by: Rapid Novor, Inc & Absolute Antibody

Our team, along with four other industry panelists, discuss ways to safeguard their research through recombinant antibodies, cell culturing procedures, antibody protein sequences, and reference identifiers.

Full Webinar Panelists:

  • Andrew Bradbury, CSO at Specifica
    “Drug-Like Antibodies from Selections”
  • Michael Fiebig, VP Product Portfolio & Innovation at Absolute Antibody
    “Why Go Recombinant? Take Your Experiments Further…”
  • Alicia Henn, CSO at BioSpherix
    “Truly Reproducible Conditions for Cells and Tissues”
  • Zac McDonald, Sr. Scientist & Manager at Rapid Novor
    “Safeguarding Research with De Novo Protein Sequencing”
  • Anita Bandrowski, CEO at SciCrunch
    “Why Should You Support RRIDs?”

Webinar details

July 15, 2020

10am Eastern Time

Brief background on reproducibility challenges in life sciences

Reproducibility is an integral part of research, and in particular in the life sciences where multiple variables are inherent to experiments with biological reagents. Particularly, antibodies are a central and critical part of this research but reproducibility is a challenge often associated with their success across a variety of applications.

Sign up for the newsletter.

Sign up for the next webinar.

Whitepaper: Prevalence of Secondary Light Chains

Talk to Our Scientists.

We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 3000 antibodies and we are eager to help you.